BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 21474575)

  • 1. Clinical assessment and determinants of chronic allograft nephropathy in maintenance renal transplant patients.
    Grinyo JM; Saval N; Campistol JM;
    Nephrol Dial Transplant; 2011 Nov; 26(11):3750-5. PubMed ID: 21474575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
    Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors of long-term graft loss in renal transplant recipients with chronic allograft dysfunction.
    Khalkhali HR; Ghafari A; Hajizadeh E; Kazemnejad A
    Exp Clin Transplant; 2010 Dec; 8(4):277-82. PubMed ID: 21143092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
    Gullestad L; Iversen M; Mortensen SA; Eiskjaer H; Riise GC; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Gude E; Rundqvist B; Fagertun HE; Solbu D; Bergh CH
    Transplantation; 2010 Apr; 89(7):864-72. PubMed ID: 20061999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The natural history of renal function following orthotopic heart transplant.
    Al Aly Z; Abbas S; Moore E; Diallo O; Hauptman PJ; Bastani B
    Clin Transplant; 2005 Oct; 19(5):683-9. PubMed ID: 16146562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
    Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients.
    Stallone G; Infante B; Schena A; Battaglia M; Ditonno P; Loverre A; Gesualdo L; Schena FP; Grandaliano G
    J Am Soc Nephrol; 2005 Dec; 16(12):3755-62. PubMed ID: 16236802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The natural history of chronic allograft nephropathy.
    Nankivell BJ; Borrows RJ; Fung CL; O'Connell PJ; Allen RD; Chapman JR
    N Engl J Med; 2003 Dec; 349(24):2326-33. PubMed ID: 14668458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure.
    Waid T;
    Clin Transplant; 2005 Oct; 19(5):573-80. PubMed ID: 16146546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and risk factors of renal dysfunction after liver transplant: a single-center experience.
    Dehghani SM; Derakhshan A; Taghavi SA; Gholami S; Jalaeian H; Malek-Hosseini SA
    Exp Clin Transplant; 2008 Mar; 6(1):25-9. PubMed ID: 18405241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
    Luna E; Cerezo I; Macias R; Villa J; Martinez C; Cubero J; Martinez R; Ferreira F; García C
    Transplant Proc; 2011; 43(6):2187-90. PubMed ID: 21839229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of chronic allograft dysfunction by switch over to rapamycin.
    Sundaram V; Abraham G; Fathima N; Sundaram V; Reddy YN; Mathew M; Sathiah V
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):37-42. PubMed ID: 20061690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why does kidney allograft fail? A long-term single-center experience.
    Alarrayed S; El-Agroudy A; Al-Arrayed A; Ghareeb S; Farid E; Garadah T; Abdulla S
    Saudi J Kidney Dis Transpl; 2011 Jul; 22(4):818-24. PubMed ID: 21743242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.